Ado-trastuzumab emtansine has the best effect after several courses of treatment

Ado-trastuzumab emtansine is a drug that targets HER2-positive breast cancer. Trastuzumab is commonly used to treat advanced or metastatic HER2-positive breast cancer. There is no universal answer to the optimal number of courses of trastuzumab as it depends on the specific circumstances of each patient. Treatment plans are usually developed by a doctor based on the patient's condition, medical history, and treatment goals.

The HER2 protein is produced by some breast tumors. Trastuzumab interferes with the growth of this protein, which also prevents tumor growth. The tumor cells are then destroyed by the body. In clinical trials, trastuzumab was typically administered at doses every 3-4 weeks until disease progression or intolerance. Depending on the condition, treatment may last several months or longer. The effectiveness of the optimal course of treatment depends on a variety of factors, including the characteristics of the tumor, the patient's overall health, and the progression of the disease before and after treatment. Therefore, it is very important for patients to undergo regular evaluation and monitoring during treatment with trastuzumab, so that the treatment plan can be adjusted in a timely manner.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.